Popma JJ, Coller BS, Ohman EM, et al. Antithrombotic therapy in patients undergoing coronary angioplasty . Chest1995; 108:486S.
2.
Cook DJ, Guyatt GH, Laupacis A., et al. Clinical recommendations using levels of evidence for antithrombotic agents. Chest1995; 108: 227S.
3.
Gruntzig AR, Senning A., Siegenthaler WENonoperative dilatation of coronary-artery stenosis. N Engl J Med1979;301:61.
4.
Topol EJ, Bonan R., Jewitt D., et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation1993;87:1622.
5.
Ferguson JJ, Dohmen P., Wilson JM, et al. Results of a national survey on anticoagulation for PTCA. J Invas Cardiol1995;7:136.
6.
Bull BS, Huse WM, Braver FS, et al. Heparin therapy during extracorporeal circulation. II. The use of a dose response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg1975;69:685.
7.
Young JA, Kisker CT, Doty DBAdequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg1978;26:231.
8.
Avendano A., Ferguson JJComparison of HemoChron and Hemo-Tec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol1994;23:907.
9.
Dougherty KG , Gaos CM, Bush HS, et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cath Cardiovasc Diag1992;26:260.
10.
Hattersley PGActivated coagulation time of whole blood . JAMA1966;196:150.
11.
Ferguson JJ , Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty . J Am Coll Cardiol1994 ; 23:1061.
12.
McGarry TF, Gottlieb RS, Morganroth J., et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J1992; 123:1445.
13.
Kem MJ, Deligonul U., Presant S., et al. Resolution of intraluminal thrombus with augmentation of heparin during percutaneous transluminal coronary angioplasty. Am J Cardiol1986;58:852.
14.
Grayburn PA , Willard JE, Brickner ME, et al. In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization . Cath Cardiovasc Diag1991;23:141.
15.
Gabliani G. , Delingonul U., Kem MJ, et al. Acute coronary occlusion occurring after successful percutaneous transluminal coronary angioplasty: temporal relationship to discontinuation of anticoagulation. Am Heart J1988;116:696.
16.
Narins CR, Hillegass WB, Nelson CL, et al. Activated clotting time predicts abrupt closure risk during angioplasty [Abstract]. J Am Coll Cardiol1994;23:470A.
17.
Ahmed WH, Meckel CR, Grines CL, et al. Relation between ischemic complications and activated clotting times during coronary angioplasty: different profiles for heparin and hirulog [Abstract]. Circulation1995;92:1-608.
18.
Ogilby JD, Kopelman HA, Klein LW, et al. Adequate heparinization during PTCA: assessment using activated clotting times. Cath Cardiovasc Diag1989; 18:206.
19.
Vaitkus PT, Herrmann HC, Laskey WKManagement and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty. Am Heart J1992; 124: 1.
20.
Ellis SG, Roubin GS, Wilentz J., et al. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J1989; 117:777.
21.
Friedman HZ , Cragg DR, Glazier SM, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol1994 :24: 1214.
22.
Oweida SW, Roubin GS, Smith RB, et al. Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. J Vasc Surg1990; 12:310.
23.
Popma JJ, Satler LF, Pichard AD, et al, Vascular complications after balloon and new device angioplasty . Circulation1993;88: 1569.
24.
Moscucci M. , Mansour KA, Kent KC, et al. Peripheral vascular complications of directional coronary atherectomy and stenting: predictors, management, and outcome. Am J Cardiol1994 ;74:448.
25.
Muller Dwm, Shamir KJ, Ellis SG, et al, Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol1992;69:63.
26.
Schwartz L. , Bourassa MG, Lesperance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med1988;318:1714.
27.
White CW, Chaitman B., Lassar TA, et al. Antiplatelet agents are effective in reducing the immediate complications of PTCA: results from the Ticlopidine Multicenter Trial [Abstract] . Circulation1987;76:IV-400.
28.
Bamathan ES , Schwartz JS, Taylor L., et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation1987;76:125.
29.
Lembo NJ, Black Ajr, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol1990;65:422.
30.
Mufson L., Black A., Roubin G., et al. A randomized trial of aspirin in PTCA: effects of high vs low dose aspirin on major complications and restenosis [Abstract]. J Am Coll Cardiol1988; 11:236A.
31.
Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol1992;19:1641.
32.
Detre K., Holubkov R., Kelsey S., et al. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. N Engl J Med1988;318:265.
33.
Topol EJNovel antithrombotic approaches to coronary artery disease. Am J Cardiol1995;75:27B.
34.
The EPIC investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med1994;330:956.
35.
Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet1994; 343;881.
36.
Ferguson JJIMPACT II results announced. Circulation1995;92: 697.
37.
Serruys PW, Herrman J-PR, Simon R., et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med1995 ;333:757.
38.
Bittl JA, Strony J., Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med1995;333:764.
39.
Serruys PW, de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon,angiop4sty in patients with coronary artery disease. N Engl J Med1994;331:489.
40.
George BS, Voorhees WD, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol1993;22:135.
41.
Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med1994;331:496.
42.
Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med1991;324:13.
43.
Schatz RA, Baim DS, Leon M., et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation1991;83:148.
44.
Nath FC, Muller Dwm, Ellis SG, et al. Thrombosis of a flexible coil coronary stent. frequency, predictors and clinical outcome. J Am Coll Cardiol1993 ;21:622.
45.
Colonibo A. , Hall P., Nakamura S., et al. Intracoronary stenting without anticoagulation accomplished with intravascular uhrasound guidance . Circulation1995;91:1676.
46.
Colombo A., Nakamura S., Hall P., et al. A prospective study of Wiktor coronary stent imputation treated only with antiplatelet therapy [Abstract]. Circulation1994;90:1-124.
47.
Elias J., Monassier JP, Puel J., et al. Medtronic Wiktor stent implantation without Coumadin: hospital outcome [Abstract]. Circulation1994;90:1-124.
48.
Hall P., Colombo A., Nakamura S., et al. A prospective study of Gianturco-Roubin coronary stent implantation without subsequent anticoagulation [Abstract]. Circulation1994;90:1-124.
49.
Aubry P., Royer T., Spaulding C., et al. Coronary stenting without Coumadin: Phase 11 and 111. The Bail-out Group [Abstract]. Circulation1994;90:1-124.
50.
Blengino S.Maietto L.Hall P., et al. Randomized trial of coronary stent imglantatican without anticoagutation: aspirin vs ticlopidine [Abstract]. Circulation1994.90:1-124.
51.
Morice M-C.Bourdonnec C., Lefevre T., et al. Coronary stenting without Coumadin. Phase III [Abstract]. Circulation1994;90; 1-125.
52.
Carvalho H. , Fajadet J., Jordan C., et al. A lower rate of complications after Gianturco-Roubin coronary stenting using a new antiplatelet and anticoagulant protocol [Abstract]. Circulation1994;90:I-125.
53.
Jordan C. Carvalho H, Fajadet J., et al. Reduction of subacute thrombosis rate after coronary stenting using a new anticoagulant protocol [Abstract] . Circulation1994;90:1-125.
54.
Femandez-Aviles F., Alonso J., Duran JM, et al. Absence of bleeding and subacute occlusion after Palmaz-Schatz coronary stenting using a new antithrombotic regimen [Abstract] . J Am Coll Cardiol1995 ; 25:196A.
55.
Blengino S. , Nakarnurra S., Hall P.A cost analysis of intravascular ultrasound guided coronary stenting without anticoagulation vs the traditional method of stenting with anticoagulation [Abstract]. J Am Coll Cardiol1995;25:197A.
56.
Blasini R., Mudra H., Schuhlen H., et al. Intravascular ultmsound guided optimized emergency coronary Patmaz-Schatz stent placement without post procedural systemic anticoagulafion [Abstract]. J Am Coll Cardiol1995:25:197A.
57.
Van Belle E. , McFadden EP, Bauters C., et al. Combined antiplatelet therapy without anticoagulation: an effective alternative to prevent subacute thrombosis after coronary stenting? A 3 month follow-up [Abstract]. J Am Coll Cardiol1995;25:197A.
58.
Hall P., Colombo A., Itoh A., et al. Gianturco-Roubin stent imptantation in small vessels without anticoagulation [Abstract]. Circulation1995 ;92:1-795.
59.
Haase J., Reifart N., Baier T., et al. Bail-out stenting (Palmaz-Schatz) without anticoagulation [Abstract] . Circulation1995;92:1-795.
60.
Wong SC, Hong MK, Chuang YC, et al. The anti-platelet treatment after intravascutaruttrasound guided optimal stent expansion (APLAUSE) trial [Abstract]. Circulation1995;92:1-795.
61.
Morice MC, Amor M., Benveniste E. et al. Coronary stenting without Coumadin Phase II, III, IV, V. Predictors of major complications [Abstract]. Circulation1995;92:1-795.
62.
Goods CM, Al-Shaibi K., lyer S.Flexible coil coronary stenting without anticoagulation or intravascular ultrasound: a prospective observational study [Abstract]. Circulation1995;92:1-795.
63.
Belli G., Whitlow PL, Gross L., et al. Intracoronary stenting without oral anticoagulation: the Cleveland Clinic Registry [Abstract]. Circulation1995 ;92:I-796.
64.
Morice MC, Breton C., Bunouf P., et al. Coronary stenting without anticoagulant, without intravascular ultrasound. Results of the French Registry [Abstract]. Circulation1995;92:I-796.
65.
Goods CM, Liu MW, liyer SS, et al. A cost analysis of coronary stenting without anticoagulation versus stenting with anticoagulation using warfarin [Abstract]. Circulation1995;92:I-796.
66.
Taylor MADiBlasi SL, Bender RM, et al. Adult respiratory distress syndrome complicating intravenous infusion of low-molecular weight dextran. Cath Cardiovse. Diagn1994:32:249.
67.
Popma JJ, Califf RM, Topol EJClinical trials of restenosis after coronary angioplasty. Circulation1991;84:1426.
68.
Brack MJRay S., Chauhan A., et al. The subcutaneous heparin and angioplasty restenosis prevention (SHARP) trial. J Am Coll Cardiol1995;26:947.
69.
Faxon DP, Spiro TE, Minor S., et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis (ERA) trial. Circulation1994;90:908.
70.
Thomton MA, Gruentzig AR, Holliman J., et al. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation1984;69:721.
71.
Purban, Buller N, Fox K., et al, Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon angioplasty. Br Heart J1988;60:485.
72.
Savage MP, Goldberg S., Bove AA, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Circulation1995;92.3194.
73.
Taylor RRGibbons FA, Cope GD, et al. Effects of low-dose aspirin on restenosis after coronary angioplasty . Am J Cardiol1991:68: 874.
74.
Darius H., Sellig S., Belz GG, et al. Aspirin500 mg/d is superior to 100 and 40 mg/d for prevention of restenosis following PTCA [Abstract. Circulation1994;90:1-651.
75.
Serruys PW, Putsch W., Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. Circulation1991;84: 1568.
76.
Serruys PW, Klein W., Tijssen Jpg, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Circulation1993;88:1588.
77.
Hyers T., Hull R., Weg J.Antithrombotic therapy for venous thromboembolic disease. Chest1995;108:335S.
